TICKERNERD
Menu
RGNXRGNXHealthcare · Biotechnology

RGNX Stock Forecast: REGENXBIO, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$8.09
+6.52% on the day

The 12 Wall Street analysts covering REGENXBIO, Inc. hold a median 12-month price target of $20 — +147.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$491.8M
Ticker Nerd rank
49 / 100
Median analyst target
$20
Analysts covering
12
Revenue$108.0M+405.7% y/y
Operating income$29.3M
Net income$22.7M
Free cash flow−$63.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+9.0%
1M
−7.6%
YTD
−43.8%
1Y
−33.8%
From 52W high
−49.4%
From 52W low
+43.2%
$6
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RGNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores REGENXBIO, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
71
Value
71
Quality
66
Size
52
Momentum
46
Accruals
44
Revisions
42
Growth
39
Volatility
23

Issuance (71): The share count has been shrinking and the company is not leaning on new borrowing.

Volatility (23): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RGNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RGNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26RGNXHigh $50Median $20Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
10 Buy2 Hold0 Sell
Low $10Median $20High $50

The green dot is the last close — the median target sits +147.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
25 Aug 2026BairdMaintainsOutperform$32 → $29
25 Aug 2026HC Wainwright & Co.MaintainsBuy$23 → $21
10 Aug 2026HC Wainwright & Co.MaintainsBuy—
10 Aug 2026HC Wainwright & Co.MaintainsBuy$26 → $23
7 Aug 2026BarclaysDowngradeEqual-Weight—
7 Aug 2026BarclaysDowngradeEqual-Weight$12
24 June 2026HC Wainwright & Co.ReiteratesBuy—
24 June 2026HC Wainwright & Co.ReiteratesBuy$26
22 June 2026BairdMaintainsOutperform$27 → $32
22 June 2026BairdMaintainsOutperform—
22 June 2026Leerink PartnersMaintainsOutperform—
22 June 2026Leerink PartnersMaintainsOutperform$17 → $18
5 June 2026HC Wainwright & Co.MaintainsBuy—
15 May 2026B of A SecuritiesMaintainsBuy—
15 May 2026BarclaysMaintainsOverweight—
9 Mar 2026HC Wainwright & Co.MaintainsBuy—
6 Mar 2026Morgan StanleyMaintainsOverweight—
10 Feb 2026Chardan CapitalMaintainsBuy—
10 Feb 2026Goldman SachsMaintainsNeutral—
10 Feb 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RGNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RGNX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, REGENXBIO, Inc. returned −33.8% against +16.2% for the S&P 500, dividends included.

RGNX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26RGNXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RGNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
3
Fundamentals

REGENXBIO, Inc. (RGNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.0×

Cheaper than 86% of US stocks

Price / sales
2.8×

Cheaper than 42% of US stocks

Price / book
5.6×

Cheaper than 17% of US stocks

EV / EBITDA
−4.4×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
405.7%

Higher than 98% of US stocks

Earnings growth (YoY)
405.7%

Higher than 94% of US stocks

Gross margin
99.0%

Higher than 99% of US stocks

Operating margin
27.1%

Higher than 85% of US stocks

Net margin
−112.6%

Higher than 5% of US stocks

Returns & dividend
Return on equity
−137.6%

Higher than 10% of US stocks

Return on assets
−21.2%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

REGENXBIO, Inc. (RGNX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • REGENXBIO, Inc. has a market value of $491.8M and an enterprise value of $657.2M.

  • Revenue in the twelve months to 30 June 2026: $174.5M. The latest quarter grew 405.7% year on year.

  • Net income over the same four quarters: −$196.4M, a −112.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.79.

  • Free cash flow in the twelve months to 30 June 2026: −$249.7M.

  • Shares outstanding: 54.2M.

  • Trailing P/E: −2.0×; forward P/E: −2.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • REGENXBIO, Inc. employs 371 people — $470K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

RGNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RGNXREGENXBIO, Inc.$491.8M
49
CTMXCytomX Therapeutics, Inc.$534.0M
48
CBIOCrescent Biopharma, Inc.$521.9M
60
BLSMBlossomhill Therapeutics, Inc.$517.3M
0
NGNENeurogene, Inc.$511.5M
58
CTNMContineum Therapeutics, Inc.$510.8M
49
MPLTMapLight Therapeutics, Inc.$508.5M
12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own REGENXBIO, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RGNX news & analysis

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

PRNewsWire · 24 Sept 2026positive

REGENXBIO announced positive three-year durability data from the Phase II ALTITUDE study of investigational surabgene lomparvovec (sura-vec) for diabetic retinopathy, presented at the Retina Society Annual Scientific Meeting. Most Dose Level 3 participants with NPDR showed a greater than 2-step DRSS improvement three years after a single in-office treatment, with no vision-threatening events or additional DR treatment, and no intraocular inflammation observed with short-course prophylactic topical steroids.

Why it matters — For RGNX watchers, this positive long-term follow-up data supports the durability and safety profile of its investigational gene therapy in diabetic retinopathy.

REGENXBIO Inc. (RGNX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

REGENXBIO Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation made available. The presentation covered the company's activities at the financial healthcare industry event.

Why it matters — A presentation at a major investment bank's healthcare conference gives REGENXBIO an opportunity to communicate its pipeline and business progress to investors and industry participants.

REGENXBIO to Participate in Upcoming Investor Conferences

PRNewsWire · 8 Sept 2026neutral

REGENXBIO announced it will participate in the Baird 2026 Global Healthcare Conference, featuring a fireside chat on Tuesday, September 15 at 8:30 a.m. The company disclosed the event in a press release dated September 8, 2026.

Why it matters — Conference participation gives investors an opportunity to hear REGENXBIO's management discuss the company and its pipeline directly.

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

Zacks Investment Research · 25 Aug 2026negative

REGENXBIO's stock fell 25% after the FDA placed a clinical hold on its gene therapy RGX-121, which is being developed for MPS II. The hold followed asymptomatic spine MRI findings in five trial participants.

Why it matters — RGNX watchers would care because a clinical hold on a key pipeline candidate could delay development of RGX-121 and weigh on the company's outlook.

Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity

Seeking Alpha · 25 Aug 2026negative

Regenxbio faces a clinical hold on RGX-121 for Hunter Syndrome, which complicates milestone payments and royalty streams, though the company maintains a sufficient cash runway into Q4 2027. Pivotal data for its AbbVie-partnered eye disease program and a BLA submission for RGX-202 in DMD are slated as near-term catalysts.

Why it matters — RGNX watchers would care because the RGX-121 clinical hold and upcoming binary catalysts are significant developments that could materially affect the company's regulatory and financial outlook.

FAQ

Frequently asked questions about RGNX stock

What is the RGNX stock price forecast for 2026-2027?

The 12 Wall Street analysts covering REGENXBIO, Inc. have a median 12-month price target of $20, with estimates ranging from $10 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RGNX stock a buy right now?

Of the 12 analysts covering REGENXBIO, Inc., 10 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks REGENXBIO, Inc. 49 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RGNX?

As at 8 Oct 2026, REGENXBIO, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (71 of 100).

Will RGNX stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +147.2% from the last close, and Ticker Nerd's factor model ranks REGENXBIO, Inc. 49 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RGNX stock forecast for 2030?

No analyst covering REGENXBIO, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RGNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $50 over the next 12 months.

How has RGNX stock performed over the past year?

REGENXBIO, Inc. returned -33.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does REGENXBIO, Inc. do?

REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapy.

What is the latest news on RGNX?

The most recent item we track (PRNewsWire, 24 Sept 2026): "REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting". REGENXBIO announced positive three-year durability data from the Phase II ALTITUDE study of investigational surabgene lomparvovec (sura-vec) for diabetic retinopathy, presented at the Retina Society Annual Scientific Meeting. Most Dose Level 3 participants with NPDR showed a greater than 2-step DRSS improvement three years after a single in-office treatment, with no vision-threatening events or additional DR treatment, and no intraocular inflammation observed with short-course prophylactic topical steroids.

Company

About REGENXBIO, Inc.

REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapy. REGENXBIO Inc. develops and commercializes recombinant adeno-associated virus (AAV)–based treatments designed to deliver functional genes to cells and address genetic defects. Its current work centers on therapeutic programs in retinal, metabolic, and neurodegenerative diseases, supported by its proprietary NAV Technology Platform. The company also licenses its AAV gene-delivery technology to other biotechnology partners, combining internal drug development with platform licensing. REGENXBIO Inc. plays a specialized role in the biotechnology market by advancing gene therapy candidates and enabling broader use of AAV-based delivery systems across the life sciences industry.

CEO Mr. Curran M. Simpson M.S. · 371 employees · United States · https://www.regenxbio.com